

Supplementary Table 1 Incidence of treatment-emergent adverse events

	Overall (N=1289)	4L PEG- ELS (Selgesse®) (N=490)	2L PEG- ASC (Moviprep® or Clensia®) (N=566)	1L PEG- ASC (Plenvu®) (N=223)	p
Patients with TEAEs, n (%)	236 (16.8%)	91 (18.4%)	113 (15.7%)	38 (15.9%)	0.4
Nausea, n (%)	73 (5.7%)	32 (6.7%)	32 (5.7%)	9 (3.9%)	0.2
Vomiting, n (%)	48 (2.3%)	15 (1.6%)	15 (1.4%)	18 (6.0%)	<0.001
Abdominal pain, n (%)	26 (2.0%)	15 (3.1%)	10 (1.8%)	1 (0.4%)	0.05
Dehydration, n (%)	9 (0.7%)	4 (0.8%)	2 (0.4%)	3 (1.3%)	0.3
Patients with serious TEAEs, n (%)	0	0	0	0	-

Abbreviations: *TEAEs*: treatment-emergent adverse events; *PEG-ELS*: polyethylene glycol plus electrolyte solution; *PEG-ASC*: polyethylene glycol plus ascorbate solution.